Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

Nazli Dizman,Jonathan E. Rosenberg,Jean H. Hoffman-Censits,David I. Quinn,Daniel P. Petrylak,Matthew D. Galsky,Ulka N. Vaishampayan,Ugo De Giorgi,Sumati Gupta,Howard A. Burris,Harris S. Soifer,Gary Li,Carl L. Dambkowski,Susan Moran,Yining Ye,Siamak Daneshmand,Dean F. Bajorin,Sumanta K. Pal

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

2019

Nazli Dizman
Jonathan E. Rosenberg
Jean H. Hoffman-Censits
David I. Quinn
Daniel P. Petrylak
Matthew D. Galsky
Ulka N. Vaishampayan
Ugo De Giorgi
Sumati Gupta
Howard A. Burris
Harris S. Soifer
Gary Li
Carl L. Dambkowski
Susan Moran
Yining Ye
Siamak Daneshmand
Dean F. Bajorin
Sumanta K. Pal

4510Background: Infigratinib (BGJ398) is a potent and selective FGFR1–3 inhibitor with significant activity in patients (pts) with advanced or metastatic urothelial carcinoma (mUC) bearing FGFR3 al...

Keywords:

Carcinoma
Pathology
Cell-free fetal DNA
Medicine
upper tract
Metastatic Urothelial Carcinoma
in patient
genomic profiling
urothelial carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations